



FOR IMMEDIATE RELEASE

Notre Dame and MTTI awarded patent for fluorescent dye technology

**November 28, 2012**, West Chester, Pennsylvania, Molecular Targeting Technologies, Inc. (MTTI) announced that Bradley Smith, Emil T. Hofman Professor of Chemistry and Biochemistry, at the University of Notre Dame and researchers from Molecular Targeting Technologies Inc. (MTTI) have been awarded US Patent 8,273,875 B2, entitled "High Luminescent Compounds". The technology relates to the field of chemistry and biochemistry, and more specifically, to novel near-infrared fluorescent dyes that are photostable and resistant to quenching. The dyes belong to a novel family of squaraine rotaxanes, and they are particularly well-suited for use in bioimaging and biotechnology applications. The research that led to their discovery was supported by Government grants awarded by the National Institutes of Health

"The initial discovery of these remarkable dyes was made in late 2004 and I am very pleased with the ongoing demonstration of superior performance in bioimaging applications" Smith said. "I am very hopeful that we can develop products and imaging procedures that help researchers and eventually contribute to the well-being of our society."

"We are excited to be working with MTTI on this technology," said Richard Cox, director of Notre Dame's Office of Technology Transfer. "MTTI has a track record of producing novel molecules as research tools for the academic and industrial communities."

Some of the squaraine rotaxane dyes are already for sale under the name SRfluor, and more products will be commercially available soon.

"We believe this technology has the potential to become useful in many different fields of biotechnology," said MTTI President and CEO Chris Pak.

#### **Molecular Targeting Technologies, Inc.**

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the identification, evaluation, acquisition and development of novel technologies for diagnosis and treatment of human diseases. MTTI has licensed several proprietary technologies that allow targeting of glioma and prostate cancers as well as stroke and myocardial infarction. MTTI is also advancing a therapeutic human monoclonal antibody in China for Rabies post-exposure prophylaxis and a vaccine technology for development of a Botulinum neurotoxin vaccine and a potent human rabies vaccine. In addition, MTTI is building a research reagents business and currently offers a range of innovative fluorescence based products for in vitro and in vivo research applications. Please visit our website: [www.mtarget.com](http://www.mtarget.com) for more information.

## **University of Notre Dame**

Founded in 1842, the University of Notre Dame is the nation's pre-eminent Catholic university and rated among the top 25 of all U.S. institutions of higher learning. Notre Dame offers its nearly 12,000 students a choice of over 60 undergraduate majors, 32 master's, and 23 doctoral degree programs. Rated as a Carnegie Doctoral/Research University-Extensive, Notre Dame boasts 4 colleges, 3 schools, 10 major research institutes, more than 40 centers and special programs, and the University's well respected Hesburgh libraries system.

Contact:

Chris Pak, e-mail: [cpak@mtarget.com](mailto:cpak@mtarget.com); Tel: (610) 738-7938

Richard Cox, e-mail: [rcox@nd.edu](mailto:rcox@nd.edu); Tel: (574) 631-4551